SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-017423
Filing Date
2023-11-02
Accepted
2023-11-02 16:15:43
Documents
71
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q knsa-20230930x10q.htm   iXBRL 10-Q 2387089
2 EX-31.1 knsa-20230930xex31d1.htm EX-31.1 11333
3 EX-31.2 knsa-20230930xex31d2.htm EX-31.2 10489
4 EX-32.1 knsa-20230930xex32d1.htm EX-32.1 6300
5 EX-32.2 knsa-20230930xex32d2.htm EX-32.2 6274
  Complete submission text file 0001558370-23-017423.txt   8610820

Data Files

Seq Description Document Type Size
6 EX-101.SCH knsa-20230930.xsd EX-101.SCH 55089
7 EX-101.CAL knsa-20230930_cal.xml EX-101.CAL 58075
8 EX-101.DEF knsa-20230930_def.xml EX-101.DEF 260373
9 EX-101.LAB knsa-20230930_lab.xml EX-101.LAB 478811
10 EX-101.PRE knsa-20230930_pre.xml EX-101.PRE 377865
65 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20230930x10q_htm.xml XML 1467512
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100
Kiniksa Pharmaceuticals, Ltd. (Filer) CIK: 0001730430 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38492 | Film No.: 231372515
SIC: 2834 Pharmaceutical Preparations